Gene Therapy Companies Among Top M&A Targets In 2020
Novo Nordisk And Gilead Tipped To Spend
Executive Summary
Zolgensma shows that a gene therapy can be a commercial hit – but there is still plenty to be wary of in this cutting-edge field.
You may also be interested in...
A Decade’s Deals In Indian Pharma Point To 2020 Trends
A look at corporate acquisitions and private equity deals in the Indian pharmaceutical industry over 2010-2019 reveals some trends, lessons and targets for possible activity in 2020.
Merck’s ‘COVID Pill’ Shows Promise, But Mortality Benefits Will Be Hard To Prove
Early results from its novel antiviral are encouraging, but demonstrating life-saving qualities in a short window of time will be tricky.
Argenx’s Autoimmune Disease Blockbuster-In-Waiting Gets FDA Decision Date
The Belgium-Netherlands based company looks on course to gain US approval by the end of 2021.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports